JP2018528968A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528968A5 JP2018528968A5 JP2018514851A JP2018514851A JP2018528968A5 JP 2018528968 A5 JP2018528968 A5 JP 2018528968A5 JP 2018514851 A JP2018514851 A JP 2018514851A JP 2018514851 A JP2018514851 A JP 2018514851A JP 2018528968 A5 JP2018528968 A5 JP 2018528968A5
- Authority
- JP
- Japan
- Prior art keywords
- histone
- fmr1
- optionally
- epigenetic modulator
- epigenetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021173030A JP2022063261A (ja) | 2015-09-17 | 2021-10-22 | Ｆｍｒ１発現を調節するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562220202P | 2015-09-17 | 2015-09-17 | |
| US62/220,202 | 2015-09-17 | ||
| PCT/US2016/052294 WO2017049192A1 (en) | 2015-09-17 | 2016-09-16 | Compositions and methods for modulating fmr1 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173030A Division JP2022063261A (ja) | 2015-09-17 | 2021-10-22 | Ｆｍｒ１発現を調節するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018528968A JP2018528968A (ja) | 2018-10-04 |
| JP2018528968A5 true JP2018528968A5 (https=) | 2019-10-31 |
Family
ID=58289664
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018514851A Pending JP2018528968A (ja) | 2015-09-17 | 2016-09-16 | Ｆｍｒ１発現を調節するための組成物および方法 |
| JP2021173030A Pending JP2022063261A (ja) | 2015-09-17 | 2021-10-22 | Ｆｍｒ１発現を調節するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173030A Pending JP2022063261A (ja) | 2015-09-17 | 2021-10-22 | Ｆｍｒ１発現を調節するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11819554B2 (https=) |
| EP (1) | EP3349749B1 (https=) |
| JP (2) | JP2018528968A (https=) |
| AU (1) | AU2016324144B2 (https=) |
| CA (1) | CA2998745A1 (https=) |
| WO (1) | WO2017049192A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3299456A1 (en) * | 2016-09-26 | 2018-03-28 | Université de Strasbourg | Recombinant dgkk gene for fragile x syndrome gene therapy |
| EP3556362A1 (en) * | 2018-04-16 | 2019-10-23 | Ecole Polytechnique Federale De Lausanne (Epfl) | Sting inhibitors |
| WO2019237244A1 (en) * | 2018-06-12 | 2019-12-19 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Use of ubiquitylation of histone 2a protein |
| WO2020035866A1 (en) * | 2018-08-16 | 2020-02-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Treatment for gene reactivation |
| SG11202109112WA (en) * | 2019-02-26 | 2021-09-29 | Nogra Pharma Ltd | Fragile x mental retardation protein interfering oligonucleotides and methods of using same |
| CN111789966B (zh) * | 2020-06-29 | 2021-05-28 | 华南农业大学 | 组蛋白甲基化H3K4me3在小鼠卵巢发育中的应用 |
| CN116867487A (zh) * | 2020-07-29 | 2023-10-10 | 完美日光有限公司 | 苏拉明的制造方法 |
| US20220323553A1 (en) * | 2021-03-08 | 2022-10-13 | The Trustees Of The University Of Pennsylvania | Epigenomic editing and reactivation of targets for the treatment of Fragile X syndrome |
| WO2023064490A1 (en) * | 2021-10-13 | 2023-04-20 | Emory University | Uses of inhibitors of yth domain family proteins in the management of cognitive or developmental disorders |
| IL313936A (en) * | 2021-12-26 | 2024-08-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Methods for screening and treating fragile X syndrome |
| WO2024259063A2 (en) * | 2023-06-14 | 2024-12-19 | University Of Massachusetts | Antisense oligonucleotides as fragile x syndrome therapeutics |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4576957A (en) | 1984-07-05 | 1986-03-18 | American Cyanamid Company | N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]ureas |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US6291438B1 (en) | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
| US5858988A (en) | 1993-02-24 | 1999-01-12 | Wang; Jui H. | Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| JP2009515887A (ja) | 2005-11-11 | 2009-04-16 | ザ スクリプス リサーチ インスティテュート | 神経系疾患のための治療薬としてのヒストンデアセチラーゼ阻害剤 |
| WO2009045467A1 (en) | 2007-10-02 | 2009-04-09 | Fred Hutchinson Cancer Research Center | Methods and compositions for identifying increased risk of developing fragile x-associated disorders |
| WO2012174610A1 (en) * | 2011-06-24 | 2012-12-27 | Murdoch Childrens Research Institute | Treatment and diagnosis of epigenetic disorders and conditions |
| WO2013050405A1 (en) * | 2011-10-03 | 2013-04-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of th2 mediated diseases |
| WO2015128837A1 (en) | 2014-02-26 | 2015-09-03 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
| EP3885343A1 (en) * | 2014-11-06 | 2021-09-29 | Dana-Farber Cancer Institute, Inc. | Indole compounds as ezh2 inhibitors and uses thereof |
-
2016
- 2016-09-16 JP JP2018514851A patent/JP2018528968A/ja active Pending
- 2016-09-16 WO PCT/US2016/052294 patent/WO2017049192A1/en not_active Ceased
- 2016-09-16 EP EP16847468.2A patent/EP3349749B1/en active Active
- 2016-09-16 US US15/760,765 patent/US11819554B2/en active Active
- 2016-09-16 AU AU2016324144A patent/AU2016324144B2/en active Active
- 2016-09-16 CA CA2998745A patent/CA2998745A1/en not_active Abandoned
-
2021
- 2021-10-22 JP JP2021173030A patent/JP2022063261A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528968A5 (https=) | ||
| Huang et al. | Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes | |
| Cacabelos | Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics | |
| Beltran et al. | G-tract RNA removes Polycomb repressive complex 2 from genes | |
| Cacabelos et al. | Epigenetics of aging and Alzheimer’s disease: Implications for pharmacogenomics and drug response | |
| Kowluru et al. | Dynamic DNA methylation of matrix metalloproteinase-9 in the development of diabetic retinopathy | |
| Wang et al. | Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases | |
| Boehm et al. | Host methyltransferases and demethylases: potential new epigenetic targets for HIV cure strategies and beyond | |
| Cheng et al. | Epigenetic regulation in cell senescence | |
| Kapellos et al. | Epigenetic control of macrophage polarisation and soluble mediator gene expression during inflammation | |
| Ihezie et al. | Epigenetics in blood–brain barrier disruption | |
| Durham et al. | Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism | |
| Ohguchi et al. | The biological significance of histone modifiers in multiple myeloma: clinical applications | |
| EP3349749B1 (en) | Compositions and methods for modulating fmr1 expression | |
| Abdel-Hameed et al. | HIV-induced epigenetic alterations in host cells | |
| Kumari et al. | Polycomb group complexes are recruited to reactivated FMR1 alleles in Fragile X syndrome in response to FMR1 transcription | |
| Ma et al. | Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer | |
| Mattioli et al. | Statins and histone deacetylase inhibitors affect lamin A/C–histone deacetylase 2 interaction in human cells | |
| McCornack et al. | The function of histone methylation and acetylation regulators in GBM pathophysiology | |
| Muscolini et al. | SIRT1 modulates the sensitivity of prostate cancer cells to vesicular stomatitis virus oncolysis | |
| Habibi et al. | Emerging roles of epigenetic mechanisms in Parkinson’s disease | |
| Szyf | Epigenetic therapeutics in autoimmune disease | |
| Pao et al. | Histone deacetylases 1 and 2 in memory function | |
| Haque et al. | Chromatin and splicing | |
| Reyser et al. | Epigenetic regulation as a therapeutic target in the malaria parasite Plasmodium falciparum |